Neuro-oNcology Neuro-oNcology

We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma. Thirty eligible patients were enrolled on this study. Median age at enrollment was 10 years (range, 4–18 years). Eligible patients received TMZ (200 mg/m2 per day) by mouth for five days every four weeks. Patients received a median of nine cycles (range, 2–12 Temozolomide in children with progressive low-grade glioma